Streamline Health® Reports Fiscal Second Quarter 2024 Financial Results
Streamline Health Solutions (NASDAQ: STRM) reported fiscal Q2 2024 results, showing a net loss of ($2.8 million) compared to ($2.5 million) in Q2 2023. Total revenue decreased to $4.5 million from $5.8 million year-over-year. However, SaaS revenue grew 19% on a pro forma basis, excluding a non-renewed contract. Adjusted EBITDA improved to ($0.3 million) from ($0.9 million) in Q2 2023.
The company reiterated its $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate expectation but updated the timeline to achieve this to the second half of fiscal 2025. As of July 31, 2024, Booked SaaS ACV was $13.6 million, with $10.7 million implemented. The company won new contracts totaling $0.8 million ACV but received non-renewal notifications for $2.8 million ACV.
Streamline Health Solutions (NASDAQ: STRM) ha riportato i risultati del secondo trimestre fiscale 2024, evidenziando una perdita netta di ($2,8 milioni) rispetto a ($2,5 milioni) nel secondo trimestre 2023. I ricavi totali sono diminuiti a $4,5 milioni rispetto a $5,8 milioni rispetto all'anno precedente. Tuttavia, i ricavi da SaaS sono cresciuti del 19% su base pro forma, escludendo un contratto non rinnovato. L'EBITDA rettificato è migliorato a ($0,3 milioni) rispetto a ($0,9 milioni) nel secondo trimestre 2023.
La società ha ribadito l'aspettativa di un tasso di pareggio dell'EBITDA rettificato per un ARR SaaS implementato di $15,5 milioni, ma ha aggiornato la tempistica per raggiungere questo obiettivo nella seconda metà dell'esercizio fiscale 2025. Al 31 luglio 2024, il Booked SaaS ACV era di $13,6 milioni, con $10,7 milioni implementati. La società ha vinto nuovi contratti per un valore totale di $0,8 milioni di ACV, ma ha ricevuto notifiche di non rinnovo per $2,8 milioni di ACV.
Streamline Health Solutions (NASDAQ: STRM) presentó los resultados del segundo trimestre fiscal de 2024, mostrando una pérdida neta de ($2,8 millones) en comparación con ($2,5 millones) en el segundo trimestre de 2023. Los ingresos totales disminuyeron a $4,5 millones desde $5,8 millones año con año. Sin embargo, los ingresos de SaaS crecieron un 19% en base pro forma, excluyendo un contrato no renovado. El EBITDA ajustado mejoró a ($0,3 millones) desde ($0,9 millones) en el segundo trimestre de 2023.
La compañía reiteró su expectativa de tasa de equilibrio del EBITDA ajustado para un ARR SaaS implementado de $15,5 millones, pero actualizó el cronograma para lograr esto a la segunda mitad del ejercicio fiscal 2025. Al 31 de julio de 2024, el Booked SaaS ACV era de $13,6 millones, con $10,7 millones implementados. La compañía ganó nuevos contratos que totalizan $0,8 millones de ACV, pero recibió notificaciones de no renovación por $2,8 millones de ACV.
Streamline Health Solutions (NASDAQ: STRM)는 2024 회계년도 2분기 결과를 보고하며, 2023년 2분기 ($2.5백만)과 비교해 ($2.8백만)의 순손실을 보였습니다. 총 수익은 작년 대비 $5.8백만에서 $4.5백만으로 감소했습니다. 그러나, SaaS 수익은 갱신되지 않은 계약을 제외하고도 프로 포르마 기준으로 19% 증가했습니다. 조정된 EBITDA는 2023년 2분기 ($0.9백만)에서 ($0.3백만)으로 개선되었습니다.
회사는 $15.5백만의 구현된 SaaS ARR 조정 EBITDA 손익 분기점 예상치를 재확인했지만, 이를 달성하는 데 걸리는 시간을 회계연도 2025년 하반기로 업데이트했습니다. 2024년 7월 31일 현재, Booked SaaS ACV는 $13.6백만이며, $10.7백만이 구현되었습니다. 회사는 총 $0.8백만 ACV에 해당하는 신규 계약을 수주했지만, $2.8백만 ACV에 대한 갱신되지 않은 통지를 받았습니다.
Streamline Health Solutions (NASDAQ: STRM) a publié les résultats du deuxième trimestre fiscal 2024, affichant une perte nette de ($2,8 millions) par rapport à ($2,5 millions) au deuxième trimestre 2023. Le chiffre d'affaires total a diminué de $5,8 millions à $4,5 millions par rapport à l'année précédente. Cependant, les revenus SaaS ont augmenté de 19 % sur une base pro forma, excluant un contrat non renouvelé. L'EBITDA ajusté s'est amélioré pour atteindre ($0,3 millions) contre ($0,9 millions) au deuxième trimestre 2023.
L'entreprise a réitéré son attente d'un taux de rentabilité de l'EBITDA ajusté pour un ARR SaaS mis en œuvre de 15,5 millions de dollars, mais a mis à jour le calendrier pour atteindre cet objectif dans la seconde moitié de l'exercice fiscal 2025. Au 31 juillet 2024, le Booked SaaS ACV était de 13,6 millions de dollars, avec 10,7 millions de dollars mis en œuvre. L'entreprise a remporté de nouveaux contrats totalisant 0,8 million de dollars ACV, mais a reçu des notifications de non-renouvellement pour 2,8 millions de dollars ACV.
Streamline Health Solutions (NASDAQ: STRM) hat die Ergebnisse des zweiten fiskalischen Quartals 2024 veröffentlicht und berichtet von einem Nettoverlust von ($2,8 Millionen) im Vergleich zu ($2,5 Millionen) im zweiten Quartal 2023. Die Gesamteinnahmen sind von $5,8 Millionen im Vorjahr auf $4,5 Millionen gesunken. Allerdings stiegen die SaaS-Einnahmen auf einer pro forma Basis um 19%, ohne einen nicht erneuerten Vertrag zu berücksichtigen. Das angepasste EBITDA verbesserte sich auf ($0,3 Millionen) von ($0,9 Millionen) im zweiten Quartal 2023.
Das Unternehmen bekräftigte seine Erwartung einer EBITDA-Break-even-Rate von $15,5 Millionen für implementiertes SaaS ARR, aktualisierte jedoch den Zeitrahmen für die Erreichung dieses Ziels auf die zweite Hälfte des fiskalischen Jahres 2025. Zum 31. Juli 2024 betrug das Booked SaaS ACV $13,6 Millionen, wobei $10,7 Millionen implementiert sind. Das Unternehmen gewann neue Verträge mit einem Gesamtwert von $0,8 Millionen ACV, erhielt jedoch Nichtverlängerungsbenachrichtigungen über $2,8 Millionen ACV.
- SaaS revenue grew 19% on a pro forma basis in Q2 2024
- Adjusted EBITDA improved to ($0.3 million) from ($0.9 million) in Q2 2023
- Company won new contracts totaling $0.8 million of ACV in Q2 2024
- $10.7 million of Booked SaaS ACV implemented as of July 31, 2024
- Net loss increased to ($2.8 million) from ($2.5 million) in Q2 2023
- Total revenue decreased to $4.5 million from $5.8 million year-over-year
- Received non-renewal notifications for contracts with $2.8 million ACV
- Delayed expectation for achieving SaaS ARR adjusted EBITDA breakeven run rate to second half of fiscal 2025
Insights
Streamline Health's Q2 2024 results show mixed signals. While the company's net loss widened to
The company's focus on SaaS solutions is evident, with SaaS revenue now accounting for
However, the reduction in Booked SaaS ACV from
The healthcare revenue cycle management market is experiencing significant transformation and Streamline Health's results reflect both opportunities and challenges in this space. The company's focus on SaaS solutions aligns with the industry trend towards cloud-based, automated revenue cycle management tools. However, the reported client non-renewals, including reasons such as full outsourcing of health system revenue cycles, indicate evolving customer preferences and competitive pressures.
The company's product enhancements for workforce automation and opportunity identification demonstrate efforts to stay relevant in a rapidly changing market. However, the revised timeline for achieving the adjusted EBITDA breakeven run rate suggests that market adoption may be slower than initially anticipated. The unpredictability in closing new contracts, as mentioned by the company, further underscores the competitive nature of the healthcare RCM software market.
Investors should closely monitor Streamline Health's ability to expand its client base and improve client retention, as these factors will be important for the company's long-term success in this dynamic market environment.
- Net loss of (
$2.8 million ) during the second quarter of fiscal 2024 compared to a net loss of ($2.5 million ) during the second quarter of fiscal 2023 - Adjusted EBITDA improved to a loss of (
$0.3 million ) for the second quarter of fiscal 2024 compared to a loss of ($0.9 million ) for the second quarter of fiscal 2023 - Company reiterated
$15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate expectation - Company updated expectation for achievement of SaaS ARR adjusted EBITDA breakeven run rate to the second half of fiscal 2025
ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the second quarter of fiscal 2024, which was the three month period ended July 31, 2024, and the six-month period ended July 31, 2024.
Fiscal Second Quarter and Six-Months Ended July 31, 2024 GAAP Financial Results
The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”).
Total revenue for the second quarter of fiscal 2024 was
SaaS revenue for the second quarter of fiscal 2024 totaled
Net loss for the second quarter of fiscal 2024 was (
Cash and cash equivalents as of July 31, 2024, were
Fiscal Second Quarter and Six Months Ended July 31, 2024 Non-GAAP Financial Results
Adjusted EBITDA for the second quarter of fiscal 2024 was (
As of July 31, 2024, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
The Company reiterated that it believes its adjusted EBITDA breakeven run rate is
Management Commentary
“During the first half of this year we have expanded the value we provide to the healthcare revenue cycle through our product enhancements for workforce automation and opportunity identification,” stated Ben Stilwill, President and Chief Executive Officer of the Company. “The Streamline team is focused on expanding our client footprint, maintaining a high caliber of client service, improving our solutions and progressing our financial goals and our mission to ensure our nation’s health systems are paid for all of the care they provide.”
Conference Call
The Company will conduct a conference call on Thursday, September 12, 2024, at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Thursday, September 12, 2024 at 12:00 PM ET to Thursday, September 19, 2024 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13748721. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, restructuring expenses, impairment of goodwill and long-lived assets and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related alignment expenses, associate inducements, and professional and advisory fees. A table reconciling this measure to “net loss,” to the extent relevant items were recognized in the periods covered, is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, anticipated cost savings from previously announced strategic restructuring, expected improved implementation timelines and lower expenses for our clients, industry trends and market growth, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, achievement of a breakeven SaaS ARR run rate, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to generate cash from operations, the availability of additional debt and equity financing to fund the Company’s ongoing operations, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Company Contact
Jacob Goldberger
Vice President, Finance
303-887-9625
jacob.goldberger@streamlinehealth.net
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (rounded to the nearest thousand dollars, except share and per share information) | |||||||||||||||
| Three Months Ended July 31, | Six Months Ended July 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues: | |||||||||||||||
| Software as a service | $ | 3,078,000 | $ | 3,531,000 | $ | 5,801,000 | $ | 6,706,000 | |||||||
| Maintenance and support | 883,000 | 1,100,000 | 1,773,000 | 2,257,000 | |||||||||||
| Professional fees and licenses | 515,000 | 1,139,000 | 1,233,000 | 2,139,000 | |||||||||||
| Total revenues | 4,476,000 | 5,770,000 | 8,807,000 | 11,102,000 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of software as a service | 1,495,000 | 1,893,000 | 2,844,000 | 3,482,000 | |||||||||||
| Cost of maintenance and support | 43,000 | 32,000 | 84,000 | 121,000 | |||||||||||
| Cost of professional fees and licenses | 840,000 | 1,022,000 | 1,727,000 | 2,130,000 | |||||||||||
| Selling, general and administrative expense | 2,989,000 | 4,116,000 | 6,181,000 | 7,957,000 | |||||||||||
| Research and development | 1,324,000 | 1,305,000 | 2,435,000 | 3,006,000 | |||||||||||
| Total operating expenses | 6,691,000 | 8,368,000 | 13,271,000 | 16,696,000 | |||||||||||
| Operating loss | (2,215,000 | ) | (2,598,000 | ) | (4,464,000 | ) | (5,594,000 | ) | |||||||
| Other (expense) income: | |||||||||||||||
| Interest expense | (496,000 | ) | (267,000 | ) | (961,000 | ) | (515,000 | ) | |||||||
| Valuation adjustments | (91,000 | ) | 359,000 | (115,000 | ) | 723,000 | |||||||||
| Other | (1,000 | ) | (1,000 | ) | (2,000 | ) | 31,000 | ||||||||
| Loss before income taxes | (2,803,000 | ) | (2,507,000 | ) | (5,542,000 | ) | (5,355,000 | ) | |||||||
| Income tax expense | — | (8,000 | ) | — | (61,000 | ) | |||||||||
| Net loss | $ | (2,803,000 | ) | $ | (2,515,000 | ) | $ | (5,542,000 | ) | $ | (5,416,000 | ) | |||
| Basic and Diluted Earnings Per Share: | |||||||||||||||
| Net loss per common share – basic and diluted | $ | (0.05 | ) | $ | (0.04 | ) | $ | (0.09 | ) | $ | (0.10 | ) | |||
| Weighted average number of common shares – basic and diluted | 60,110,178 | 56,357,684 | 59,167,134 | 56,164,282 | |||||||||||
| STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (rounded to the nearest thousand dollars, except share and per share information) | |||||||
| July 31, 2024 | January 31, 2024 | ||||||
| (Unaudited) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,536,000 | $ | 3,190,000 | |||
| Accounts receivable, net of allowance for credit losses of | 2,521,000 | 4,237,000 | |||||
| Contract receivables | 969,000 | 780,000 | |||||
| Prepaid and other current assets | 659,000 | 629,000 | |||||
| Total current assets | 7,685,000 | 8,836,000 | |||||
| Non-current assets: | |||||||
| Property and equipment, net of accumulated amortization of | 64,000 | 88,000 | |||||
| Capitalized software development costs, net of accumulated amortization of | 5,403,000 | 5,798,000 | |||||
| Intangible assets, net of accumulated amortization of | 11,253,000 | 12,071,000 | |||||
| Goodwill | 13,276,000 | 13,276,000 | |||||
| Other | 1,344,000 | 1,666,000 | |||||
| Total non-current assets | 31,340,000 | 32,899,000 | |||||
| Total assets | $ | 39,025,000 | $ | 41,735,000 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,413,000 | $ | 1,253,000 | |||
| Accrued expenses | 1,948,000 | 2,023,000 | |||||
| Current portion of term loan | 2,000,000 | 1,500,000 | |||||
| Deferred revenues | 6,591,000 | 7,112,000 | |||||
| Acquisition earnout liability | 577,000 | 1,794,000 | |||||
| Total current liabilities | 12,529,000 | 13,682,000 | |||||
| Non-current liabilities: | |||||||
| Term loan, net of current portion and deferred financing costs | 6,611,000 | 7,566,000 | |||||
| Line of credit | — | 1,500,000 | |||||
| Notes payable, net of deferred financing costs | 3,853,000 | — | |||||
| Deferred revenues, less current portion | 134,000 | 173,000 | |||||
| Total non-current liabilities | 10,598,000 | 9,239,000 | |||||
| Total liabilities | 23,127,000 | 22,921,000 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock, | 633,000 | 590,000 | |||||
| Additional paid in capital | 136,506,000 | 133,923,000 | |||||
| Accumulated deficit | (121,241,000 | ) | (115,699,000 | ) | |||
| Total stockholders’ equity | 15,898,000 | 18,814,000 | |||||
| Total liabilities and stockholders’ equity | $ | 39,025,000 | $ | 41,735,000 | |||
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (rounded to the nearest thousand dollars) | |||||||
| Six Months Ended July 31, | |||||||
| 2024 | 2023 | ||||||
| Net loss | $ | (5,542,000 | ) | $ | (5,416,000 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 2,290,000 | 2,134,000 | |||||
| Accrued interest expense - notes payable | 326,000 | — | |||||
| Valuation adjustments | 115,000 | (723,000 | ) | ||||
| Benefit for deferred income taxes | — | 43,000 | |||||
| Share-based compensation expense | 1,032,000 | 1,109,000 | |||||
| Provision for credit losses | (58,000 | ) | — | ||||
| Changes in assets and liabilities: | |||||||
| Accounts and contract receivables | 1,585,000 | 4,985,000 | |||||
| Other assets | (71,000 | ) | (146,000 | ) | |||
| Accounts payable | 78,000 | 31,000 | |||||
| Accrued expenses and other liabilities | (75,000 | ) | (1,361,000 | ) | |||
| Deferred revenue | (560,000 | ) | (1,592,000 | ) | |||
| Net cash used in operating activities | (880,000 | ) | (936,000 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | — | (47,000 | ) | ||||
| Capitalization of software development costs | (426,000 | ) | (1,026,000 | ) | |||
| Net cash used in investing activities | (426,000 | ) | (1,073,000 | ) | |||
| Cash flows from financing activities: | |||||||
| Repayment of bank term loan | (500,000 | ) | (250,000 | ) | |||
| Repayment of line of credit | (1,500,000 | ) | — | ||||
| Proceeds from issuance of common stock | 100,000 | — | |||||
| Proceeds from notes payable | 4,400,000 | — | |||||
| Payments of acquisition earnout liabilities | (686,000 | ) | — | ||||
| Payments for deferred financing costs | (86,000 | ) | — | ||||
| Payments related to repurchase of common shares to satisfy employee tax withholding | (77,000 | ) | (252,000 | ) | |||
| Other | 1,000 | — | |||||
| Net cash provided (used in) by financing activities | 1,652,000 | (502,000 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 346,000 | (2,511,000 | ) | ||||
| Cash and cash equivalents at beginning of period | 3,190,000 | 6,598,000 | |||||
| Cash and cash equivalents at end of period | $ | 3,536,000 | $ | 4,087,000 | |||
| STREAMLINE HEALTH SOLUTIONS, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited, rounded to the nearest thousand dollars) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| In thousands, except per share data | July 31, 2024 | July 31, 2023 | July 31, 2024 | July 31, 2023 | ||||||||||||
| Adjusted EBITDA Reconciliation | ||||||||||||||||
| Net Loss | $ | (2,803 | ) | $ | (2,515 | ) | $ | (5,542 | ) | $ | (5,416 | ) | ||||
| Interest expense | 496 | 267 | 961 | 515 | ||||||||||||
| Income tax expense | — | 8 | — | 61 | ||||||||||||
| Depreciation and amortization | 1,056 | 1,050 | 2,073 | 2,081 | ||||||||||||
| EBITDA | $ | (1,251 | ) | $ | (1,190 | ) | $ | (2,508 | ) | $ | (2,759 | ) | ||||
| Share-based compensation expense | 533 | 537 | 1,032 | 1,109 | ||||||||||||
| Non-cash valuation adjustments | 91 | (359 | ) | 115 | (723 | ) | ||||||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 325 | 119 | 356 | 176 | ||||||||||||
| Other non-recurring charges | — | — | — | (33 | ) | |||||||||||
| Adjusted EBITDA | $ | (302 | ) | $ | (893 | ) | $ | (1,005 | ) | $ | (2,230 | ) | ||||
Source: Streamline Health Solutions, Inc.
FAQ
What was Streamline Health's (STRM) SaaS revenue growth in Q2 2024?
How much was Streamline Health's (STRM) net loss in Q2 2024?
What is Streamline Health's (STRM) implemented SaaS ARR adjusted EBITDA breakeven run rate expectation?
What was Streamline Health's (STRM) Booked SaaS Annual Contract Value as of July 31, 2024?
